Literature DB >> 8382161

Lack of effect of ethyol (WR-2721) on forearm blood flow in healthy volunteers.

J R Cockcroft, J L Toy, J M Ritter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382161     DOI: 10.1007/bf00315291

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

1.  The measurement of volume changes in human limbs.

Authors:  R J WHITNEY
Journal:  J Physiol       Date:  1953-07       Impact factor: 5.182

2.  Acute cardiovascular and autonomic effects of WR-2721: a radioprotective compound.

Authors:  R W Caldwell; M H Heiffer
Journal:  Radiat Res       Date:  1975-04       Impact factor: 2.841

3.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

4.  Phase I/II trials of WR-2721 and cis-platinum.

Authors:  D Glover; J H Glick; C Weiler; K Fox; A Turrisi; M M Kligerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

5.  The role of WR-2721 in radiotherapy and/or chemotherapy.

Authors:  J M Yuhas; J M Spellman; F Culo
Journal:  Cancer Clin Trials       Date:  1980

6.  Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension.

Authors:  B F Robinson; R J Dobbs; S Bayley
Journal:  Clin Sci (Lond)       Date:  1982-07       Impact factor: 6.124

7.  Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid].

Authors:  A T Turrisi; D J Glover; S Hurwitz; J Glick; A L Norfleet; C Weiler; J M Yuhas; M M Kligerman
Journal:  Cancer Treat Rep       Date:  1986-12

8.  Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.

Authors:  J M Yuhas; J M Spellman; S W Jordan; M C Pardini; S M Afzal; F Culo
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.